Press release
Neupogen (filgrastim) Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share
Neupogen (filgrastim) Market Size
In the recent past, the market size of neupogen (filgrastim) has seen a significant surge. The sector is expected to boost from $1,330.69 million in 2024, reaching up to $1,404.70 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. Factors such as a surge in cancer cases, increased understanding of chemotherapy-induced neutropenia, enhancements in healthcare infrastructure, early green lights for Neupogen biosimilars, and a rise in global healthcare expenditure have contributed to the growth observed in the historical period.
There is a predicted robust growth in the neupogen (filgrastim) market over the coming years, expanding to a total value of $1,727.05 million in 2029 at a compound annual growth rate (CAGR) of 5.3%. This growth trajectory in the projected period can be linked to increasing requirements for affordable neutropenia treatment, the broadening of healthcare coverage in growing markets, elevated governmental backing for biosimilar penetration, an enhanced emphasis on personalized healthcare, and an aging global population. Noteworthy trends during this forecast period include escalated investment in biosimilars research and development, advancements in neutropenia treatment drug delivery systems, expanding alliances for the commercial distribution of oncology drugs, a reinforced commitment to patient affordability programs, and the creation of next-generation G-CSF products.
What Are the Primary Growth Drivers for the Neupogen (filgrastim) Market?
The growth of the neupogen (filgrastim) market is projected to be fueled by a rising prevalence of various diseases. These diseases, which may be caused by factors including infections, genetics, environmental factors, or lifestyle choices, interfere with the body's structure or functioning, causing particular symptoms or affecting specified locations. An increase in diseases is being pushed by elements such as an aging population, inactive lifestyles, rising pollution levels, unhealthy dietary habits, and the worldwide distribution of infectious diseases. Neupogen (filgrastim) helps alleviate chemotherapy-induced neutropenia complications by promoting neutrophil production, thereby augmenting the ability of the immune system to fight off infections in those with compromised immunity. Markedly, it reduces hospitalization rates, manages infection risks, and enables continuous cancer treatment for patients undergoing intense therapies. For instance, Allergy UK reported in April 2024 that allergies, the most often reported chronic health condition in 2022, impacted more than 21 million people in the UK. Additionally, Macmillan Cancer Support data from June 2022 indicated that there were 3 million people living with cancer in 2022, a figure projected to increase to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Hence, the rise in various diseases' prevalence is driving the growth of the neupogen (filgrastim) market. The growth of the neupogen (filgrastim) market is also expected to be advanced by government-led healthcare research and development initiatives. Government actions, whether at a local, regional, national, or international level, can benefit society, resolve particular issues, or help achieve certain objectives. Several government authorities are setting up numerous healthcare initiatives to support facets including neupogen (filgrastim). The Department of Health and Social Care, for example, disclosed in 2022 that the UK government had committed £260 million (US $270.65 million) to boost healthcare research and manufacturing. The monies were earmarked by BEIS and DHSC to support NHS-led health research into diagnostics and treatments via new privacy-preserving platforms and clinical research services, and to provide £60 million (US $63.60 million) to expand life sciences manufacturing in the UK. Therefore, government-led healthcare R&D initiatives are stimulating the neupogen (filgrastim) market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp
Who Are the Dominant Companies Influencing Neupogen (filgrastim) Market Trends?
Major companies operating in the neupogen (filgrastim) market include Amgen Inc.
How Is the Neupogen (filgrastim) Market Evolving?
One dominant trend within the neupogen (filgrastim) market is the emphasis on pioneering novel products, particularly filgrastim biosimilar solutions. These are designed to serve as a cost-effective and accessible alternative for managing chemotherapy-induced neutropenia. These biosimilar solutions are biological medications that replicate the original filgrastim (Neupogen), ensuring safety, efficacy, and structure primarily to encourage the production of neutrophils in chemotherapy patients, hence preventing neutropenia. For example, in November 2022, Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies operating in the pharmaceutical and biopharmaceutical sectors respectively, introduced a biosimilar referencing Neupogen (filgrastim) called Releuko (filgrastim-ayow), into the US market. Releuko, which comes in intravenous and subcutaneous formulations, is available in single-dose vials and prefilled syringes, providing dosage flexibility for healthcare providers. It holds significance as it offers an affordable treatment alternative for chemotherapy-induced neutropenia, enhances the availability of vital oncology care, and caters to the growing demand for biosimilars in the market.
What Are the Different Segmentations in the Neupogen (filgrastim) Market?
The neupogen (filgrastim)market covered in this report is segmented -
1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-
Which Region Is at the Forefront of the Neupogen (filgrastim) Market?
North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The Neupogen (filgrastim) Global Market Report?
- Market Size Analysis: Analyze the neupogen (filgrastim) Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the neupogen (filgrastim) market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall neupogen (filgrastim) market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the neupogen (filgrastim) market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neupogen (filgrastim) Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share here
News-ID: 3872726 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Neupogen
Neupogen Market Expansion Fueled by Cancer Supportive Care and Neutropenia Treat …
The qualitative latest Research report (2025-2032) on the Neupogen Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/8115
Focused on growth and future…
Neupogen Market Set to Witness Significant Growth from 2025 to 2032, Highlightin …
The Neupogen Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Neupogen industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial…
Neupogen Market Surging as Biosimilars Take Over and Supportive Cancer Care Expa …
The Global Neupogen Market is expected to decline from USD 89.2 Mn in 2025 to USD 30.5 Mn by 2032, with a negative CAGR of -14.2% over the forecast period.
The latest Neupogen Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated…
Comprehensive Neupogen (filgrastim) Market Insights: Forecasting Size, Growth, a …
How Are the key drivers contributing to the expansion of the neupogen (filgrastim) market?
The advancement of the neupogen (filgrastim) market is anticipated due to an escalating occurrence of diverse diseases. Diseases refer to irregularities in bodily functions or structures that manifest particular symptoms and commonly impact specific areas, generally induced by environmental factors, lifestyle choices, infections, or genetics. The escalating prevalence of diseases is propelled by elements like an aging…
Biosimilar Competition Market 2019 |Is Heating-up! Have You Mapped Your Competit …
Biosimilar approvals have increased steeply in the recent years. Europe leads in terms of biosimilar approvals. However, the U.S. has also shown significant growth in terms of biosimilar approvals. Sandoz’s Zarxio, a biosimilar to Amgen’s bone marrow stimulant Neupogen (filgrastim) — was the first biosimilar approved in the U.S., followed by three approvals in 2016. The number has increased to nine in 2017 and hit a record number of 16…
Global Filgrastim biosimilar market is expected to grow at rapid pace with stron …
InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ' Global Filgrastim Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2027'
Request for ToC/Proposal: https://bit.ly/2UNpfGA
Filgrastim is G-CSF that stimulates bone marrow to produce more neutrophils. The drug was developed by Amgen and marketed under the trade name of Neupogen. It was approved in the U.S. by Food Drug and Administration…
